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Dear Editor,
In  Western  countries,  HFE-linked  hereditary  hemo-
chromatosis (HH) is considered to be the most common 
cause of iron overload. The HFE gene, first identified in 
1996, is located on the short arm of chromosome 6. The 
majority of patients with phenotypic HH are homozy-
gous for the C282Y mutation, a major mutation of the 
HFE  gene,  whereas  compound  heterozygosity  (C282Y/
H63D) is found in patients with a milder iron loading 
phenotype (1). Because hepatic iron overload promotes 
liver fibrogenesis in HH, it is crucial to know whether the 
presence of any HFE gene mutations might accelerate 
liver damage.
In a study by Jowkar et al. (2) published in the Novem-
ber issue of Hepatitis Monthly, the C282Y mutation was 
not detected in cryptogenic cirrhosis patients as well as 
healthy individuals; however, 22% of the patients and 28% 
of the healthy individuals were found to be heterozy-
gous for the H63D mutation. Therefore, they concluded 
that HH is not the major cause of cryptogenic cirrhosis 
in the Iranian population. Although this study adds to 
the general knowledge on the molecular genetics of HH 
in the different regions of Iran, the findings of this study 
should be debated. We, as well as other researchers, have 
studied the frequency of HFE gene mutation among Ira-
nian patients with chronic hepatitis and healthy indi-
viduals (3-5). In the aforementioned studies, it was found 
that the allele frequency of the C282Y mutation was be-
tween 0% and 0.1%, whereas the allele frequency of the 
H63D mutation varied between 8.6 and 12.5% in healthy 
individuals. It is also noteworthy to mention that cryp-
togenic cirrhosis is a diagnosis of exclusion. Therefore, 
it is assumed that several of the patients in these stud-
ies are in fact alcoholic hepatitis or nonalcoholic steato-
hepatitis  (NASH)  patients.  The  patients’  reluctance  to 
admit to alcohol consumption along with the absence 
of advanced molecular techniques result in a higher 
number of false positive cases of cryptogenic cirrhosis in 
Iran. It is also not quite plausible to conclude that “HH is 
not a major cause of cryptogenic cirrhosis in the Iranian 
population” as Jowkar et al. have indicated in their study 
(2). Perhaps, the authors meant to say that the develop-
ment of cirrhosis in these patients cannot be attributed 
to HFE mutations. In the absence of any positive labora-
tory index of iron overload, there would be no evidence 
to correlate merely HFE mutations with hepatic cirrhosis 
even if these patients harbored HFE mutations. Taken to-
gether, our understanding of the role of HFE mutations 
in liver fibrogenesis in the context of viral hepatitis, alco-49 HFE Gene Mutations (C282Y and H63D) and Cryptogenic Cirrhotsis Sendi H et al.
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holic hepatitis, or other unknown accelerating factors is 
very premature, and further research and broader trans-
lational studies are required to unravel the underlying 
mechanisms. 
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